These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 15034522)
1. Rofecoxib-induced pseudoporphyria. Markus R; Reddick ME; Rubenstein MC J Am Acad Dermatol; 2004 Apr; 50(4):647-8. PubMed ID: 15034522 [No Abstract] [Full Text] [Related]
2. [Pseudoporphyria and coxib]. Schmutz JL; Barbaud A; Trechot P Ann Dermatol Venereol; 2006 Feb; 133(2):213. PubMed ID: 16508618 [No Abstract] [Full Text] [Related]
3. [Wrong information concerning rofecoxib]. Rygnestad T; Slørdal L Tidsskr Nor Laegeforen; 2002 Aug; 122(20):2035. PubMed ID: 12555455 [No Abstract] [Full Text] [Related]
4. Intracranial hypertension induced by rofecoxib. Jacob S; Rajabally YA Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617 [TBL] [Abstract][Full Text] [Related]
5. [Really only Vioxx?]. Heinzl S Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229 [No Abstract] [Full Text] [Related]
6. New use approved for Vioxx. FDA Consum; 2002; 36(4):3. PubMed ID: 12184302 [No Abstract] [Full Text] [Related]
7. Non-steroidal anti-inflammatory drugs in orofacial pain management--an update. van der Bijl P; van der Bijl P SADJ; 2002 Aug; 57(8):328-31. PubMed ID: 12428528 [No Abstract] [Full Text] [Related]
9. [New indication for selective COX-2 inhibitors. Now also approve for acute pain]. MMW Fortschr Med; 2002 Mar; 144(10):62. PubMed ID: 11928272 [No Abstract] [Full Text] [Related]
10. [80,000 patients with arthrosis treated. Coxib gets through a practice test, too]. MMW Fortschr Med; 2002 Oct; 144(41):60. PubMed ID: 12474372 [No Abstract] [Full Text] [Related]
11. [Rofecoxib and gynecomastia: the first case]. Schmutz JL; Barbaud A; Trechot P Ann Dermatol Venereol; 2004; 131(8-9):856. PubMed ID: 15505566 [No Abstract] [Full Text] [Related]
12. Vioxx doctors wooed by Merck are now its foes. Tesoriero HW Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911 [No Abstract] [Full Text] [Related]
13. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk]. Bijlsma JW Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407 [TBL] [Abstract][Full Text] [Related]
14. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib. Bagán JV; Thongprasom K; Scully C Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219 [TBL] [Abstract][Full Text] [Related]
15. [General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors]. MMW Fortschr Med; 2004 May; 146(21):61. PubMed ID: 15373091 [No Abstract] [Full Text] [Related]
16. Lessons on prescribing and drug safety from the withdrawal of rofecoxib. Nelson M; Cicuttini F Aust Fam Physician; 2004 Dec; 33(12):965-6. PubMed ID: 15630913 [No Abstract] [Full Text] [Related]
17. Is rofecoxib safer than naproxen? Adelman A J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204 [No Abstract] [Full Text] [Related]
18. Severe cholestasis and acute renal failure related to rofecoxib. Linares P; Vivas S; Jorquera F; Olcoz JL; de Leon B; Oritz de Urbina J Am J Gastroenterol; 2004 Aug; 99(8):1622-3. PubMed ID: 15307886 [No Abstract] [Full Text] [Related]
19. Discontinuation of Vioxx. Nutt DJ Lancet; 2005 Jan 1-7; 365(9453):28. PubMed ID: 15639676 [No Abstract] [Full Text] [Related]